Navigation Links
China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2010
Date:11/12/2010

KUNMING, China, Nov. 12, 2010 /PRNewswire-Asia-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (NYSE Amex Equities: KUN) ("China Shenghuo" or the "Company"), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People's Republic of China ("PRC"), today reported unaudited financial results for the third quarter ended September 30, 2010.

Third Quarter 2010 Financial Highlights

  • Total revenues decreased to $8.55 million for the third quarter of 2010, representing 19% year-over-year decrease.

  • Gross margin for the third quarter of 2010 decreased to $5.6 million, as compared to $7.6 million for the same period of 2009.

  • Net cash provided by operating activities increased to $2.24 million for the nine months ended September 30, 2010 from $0.88 million for the same period of 2009.

  • Net income attributable to stockholders increased to $787,657 for the third quarter of 2010, as compared to net loss of $31,924 for the same period of 2009.

  • Mr. Gui Hua Lan, Chief Executive Officer of China Shenghuo, commented, "Sales for the quarter ended September 30, 2010 was approximately $8.55 million, decreased by 19% from approximately $10.56 million for the quarter ended September 30, 2009. Net income was $787,657 for the quarter ended September 30, 2010, as compared to net loss of $31,924 for the quarter ended September 30, 2009. The decrease in sales was primarily due to our adjustment of the sales commission policy to decrease the commission to sales representatives to offset the pressure resulting from the increase of the price of raw material. The Company will continue to make efforts to promote the sales of our products and control our costs."

    Third Quarter 2010 ResultsSales: Sales for the three months ended September 30, 2010 was approximately $8.55 million, a decrease of approximately $2 million, or 19 %, from approximately $10.56 million for the three months ended September 30, 2009. The decrease was mainly due to the Company adjusted our sales commission policy to decrease the commission to sales representatives, which led to the decrease of the sales in the third quarter.

    Since the spring of 2010, we faced a challenge of insufficient supply of our major material-Sanqi in Yunnan Province, where has suffered the worst drought in 50 years from last autumn to this spring. The output of Sanqi decreased sharply, resulting in the price of Sanqi increased remarkably. In order to release the pressure from increasing cost, the Company decided to adjust our sales commission policy to decrease the commission to sales representatives by 10% as compared to that in the first quarter, which led to the decrease of the sales. The commission policy is subject to adjustment from time to time according to the sales in the market. The Company in August has slightly increased its sales commission, as a result of a slight decrease in its cost of Sanqi.

    Cost of sales: Our cost of sales for the three months ended September 30, 2010 was approximately $3 million, an increase of $0.05 million, or 2%, from approximately $2.95 million for the three months ended September 30, 2009. The increase in cost of sales was primarily due to the increase of the price of our main raw material which was caused by serious drought offset by the decreased sale volume.

    Gross margin: Our gross margin for the three months ended September 30, 2010 was approximately $5.6 million as compared with approximately $7.6 million for the three months ended September 30, 2009, a decrease of $2 million, or 27%. Gross margin as a percentage of revenues was approximately 65% for the three months ended September, 2010, a decrease of 7.1 % from 72.1% for the three months ended September 30, 2009. The decrease in gross margin percentage was primarily due to the increase of raw material price.

    Selling expense: Selling expenses were approximately $3.85 million for the three months ended September 30, 2010, a decrease of $3.14 million, or 45%, from approximately $6.99 million for the three months ended September 30, 2009. The primary reasons for the decrease in selling expenses were: i) our adjustment on the commission policy to sales representatives as set forth above; ii) the strengthened control on the travel expense, business entertainment expense, etc.; iii) the decreased expense on OTC market development as compared to that of in 2009, since when we started to expand our business into the OTC market in selected areas around China.

    General and administrative expense: General and administrative expenses were approximately $0.89 million for the three months ended September 30, 2010, a decrease of $0.17 million, or 16%, from approximately $1.06 million for the three months ended September 30, 2009, which was mainly due to strengthened control on professional fee.

    Research and development expense: Research and development expense for the three months ended September 30, 2010 was $160,795, as compared to $10,534 for the period ended September 30, 2009, an increase of approximately $150,261 or 1426%. The increase was primarily due to the increase in the expenditure on one of our innovative medicines- Dencichine Hemostat and the cooperation with external experts since late 2009.

    Other income (expenses): Other income were $298,543 for the three months ended September 30, 2010, which consisted of subsidy income, interest income, non-operating income offset by interest expense and non-operating expense, an increase of $434,546, or 320%, from expense of $136,003 for the three months ended September 30, 2009. The increase was mainly attributable to the subsidy income we received from the government in the third quarter of 2010.

    Net income (loss) attributable to shareholders: Net income increased to $787,657 for the three months ended September 30, 2010 as compared to net loss of $31,924 for the three months ended September 30, 2009. The increase in net income was primarily due to the decrease of selling expenses and increase of subsidy income.

    About China ShenghuoFounded in 1995, China Shenghuo is a specialty pharmaceutical company that focuses on the research, development, manufacture and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd., it owns thirty SFDA (State Food and Drug Administration) approved medicines, including the flagship product Xuesaitong Soft Capsules, which is currently being listed in the 2010 Provincial Insurance Catalogue of eleven provinces and remains to be listed in the 2009 Provincial Insurance Catalogue of fourteen provinces around China.  At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Singapore, Japan, Malaysia, and Thailand and to European countries such as the United Kingdom, Tajikistan, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn.

    Safe Harbor StatementThis press release may contain certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, risks of litigation and governmental or other regulatory proceedings arising out of or related to any of the matters described in recent press releases, including arising out of the restatement of the Company's financial statements; the Company's ability to refinance or repay loans received; the Company's uncertain business condition; the Company's continuing ability to satisfy any requirements which may be prescribed by the Exchange for continued listing on the Exchange; risks arising from potential weaknesses or deficiencies in the Company's internal controls over financial reporting; the Company's reliance on one supplier for Sanchi; the possible effect of adverse publicity on the Company's business, including possible contract cancellation; the Company's ability to develop and market new products; the Company's ability to establish and maintain a strong brand; the Company's continued ability to obtain and maintain all certificates, permits and licenses required to open and operate retail specialty counters to offer its cosmetic products and conduct business in China; protection of the Company's intellectual property rights; market acceptance of the Company's products; changes in the laws of the People's Republic of China that affect the Company's operations; cost to the Company of complying with current and future governmental regulations; the impact of any changes in governmental regulations on the Company's operations; general economic conditions; and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Contact:China Shenghuo Pharmaceutical Holdings, Inc.Ms. Shujuan WangSecretary of the Board of DirectorsEmail: wangshujuan@chinashenghuo.net Tel: +86-871-728-2698CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in USD)September 30,December 31,20102009(Unaudited)Assets:Current Assets:   Cash and cash equivalents$

    1,703,422$

    1,986,540   Accounts and notes receivable, net13,351,44612,104,296   Other receivables, net7,013,6556,694,151   Advances to suppliers851,322394,856   Inventories, net 3,102,9373,896,358   Due from related parties216,503417,494   Other current assets1,177,984866,645Total Current Assets27,417,26926,360,340   Property, plant and equipment, net 14,414,49512,065,552Other non-current assets1,718,1471,497,421$

    43,549,911$

    39,923,313Liabilities and Equity:Current Liabilities:   Accounts payable$

    3,240,471$

    4,744,919   Other payables and accrued expenses9,587,56510,099,497   Deposits payable7,915,2677,037,155   Short-term borrowings5,008,7085,455,958   Advances from customers2,006,222916,362   Taxes and related payables943,7011,094,331   Current portion of long-term borrowings7,013,7743,948,985Total Current Liabilities35,715,70833,297,207Long-term borrowings6,327,3195,850,34842,043,02739,147,555Commitments and Contingencies--Equity:   Common stock, $0.0001 par value, 100,000,000 shares1,9681,968authorized and 19,679,400 shares outstanding   Additional paid-in capital6,193,9276,193,927   Appropriated retained earnings147,023147,023   Accumulated deficit(6,398,473)(7,157,293)   Accumulated other comprehensive income1,614,0511,589,047   Total stockholder's equity1,558,496774,672Noncontrolling interests(51,612)1,086Total Equity1,506,884775,758$

    43,549,911$

    39,923,313CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSAND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)(Amounts in USD, except shares)Three months Ended  September 30,Nine months ended September 30,2010200920102009Sales $

    8,551,182$

    10,558,218$

    23,340,191$

    25,459,077Cost of Sales2,996,6742,947,5117,561,6507,643,566Gross Margin5,554,5087,610,70715,778,54117,815,511Operating Expenses:   Selling expenses3,849,3476,988,01711,869,16419,604,857   General and administrative expenses894,3011,063,9812,493,7495,230,722   Research and development expense160,79510,534417,18424,4554,904,4438,062,53214,780,09724,860,034Income(Loss) from Operations650,065(451,825)998,444(7,044,523)Other Income (Expenses):    Subsidy income492,45149,723654,013194,902   Interest income(expense), net(213,683)(182,879)(653,722)(701,581)   Other income42,282-228,046-   Other expense(22,507)(2,847)(292,647)(22,038)298,543(136,003)(64,310)(528,717)Income (Loss) Before Income Tax948,608(587,828)934,134(7,573,240)Income tax benefit (expense)(118,370)401,012(141,001)401,012Net Income (Loss )830,238(186,816)793,133(7,172,228)Net income(loss) attributable to

     noncontrolling interests42,581(154,892)34,313(403,257)Net Income(Loss) Attributable to Common Stockholders$

    787,657$

    (31,924)$

    758,820$

    (6,768,971)Comprehensive Income (Loss):  Net Income (Loss)830,238(186,816)793,133(7,172,228)Foreign currency translation

     adjustment21,221(76,185)26,13573,064Comprehensive Income (Loss):$

    851,459$

    (263,001)$

    819,268$

    (7,245,292)Comprehensive income (loss)

     attributable to noncontrolling interests42,617(158,693)35,444(406,947)Comprehensive Income

    (Loss) Attributable to Common Stockholders808,842(104,308)783,824(6,838,345)Basic and diluted earnings (loss) per share$

    0.04$

    (0.00)$

    0.04$

    (0.34)Weighted-average number of shares outstanding-basic and diluted19,679,40019,679,40019,679,40019,679,400CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)(Amounts in USD)Nine months Ended September 30,20102009Net Cash Provided by Operating Activities2,239,891878,694Cash Flows from Investing Activities:Purchase of long-lived assets(5,607,809)(738,350)Proceeds from disposal of property, plant and equipment 308,229Net Cash Used in Investing Activities(5,299,580)(738,350)Cash Flows from Financing Activities:Due to related parties-(345,371)Proceeds from borrowings24,640,17221,227,417Payments on borrowings(21,904,375)(19,915,434)Net Cash Provided by Financing Activities 2,735,797966,612Effect of exchange rate changes on cash 40,7754,706Net Change in Cash and Cash Equivalents(283,117)1,111,662Cash and Cash Equivalents at Beginning of Period1,986,5401,612,054Cash and Cash Equivalents at End of Period$1,703,423$2,723,716Supplemental InformationCash paid for interest

    $

    543,799$

    704,242Cash paid for income tax

    $

    130,489$

    -
    '/>"/>

    SOURCE China Shenghuo Pharmaceutical
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
    2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
    3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
    4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
    5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
    6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
    7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
    8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
    9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
    10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
    11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
    (Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
    (Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
    (Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
    (Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
    (Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
    (Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
    Breaking Medicine News(10 mins):